Entellus Medical, Inc. (NASDAQ:ENTL) VP Kevin L. Mensink sold 2,500 shares of the stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $19.00, for a total value of $47,500.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Kevin L. Mensink also recently made the following trade(s):

  • On Monday, October 16th, Kevin L. Mensink sold 10,000 shares of Entellus Medical stock. The shares were sold at an average price of $18.29, for a total value of $182,900.00.

Shares of Entellus Medical, Inc. (ENTL) traded down 0.77% during trading on Tuesday, reaching $18.06. The company had a trading volume of 133,674 shares. Entellus Medical, Inc. has a 12 month low of $11.47 and a 12 month high of $20.56. The stock has a 50 day moving average price of $18.36 and a 200 day moving average price of $18.36. The firm’s market capitalization is $458.20 million.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. On average, equities research analysts forecast that Entellus Medical, Inc. will post ($1.61) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Entellus Medical, Inc. (ENTL) VP Sells $47,500.00 in Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/24/entellus-medical-inc-entl-vp-sells-47500-00-in-stock.html.

Several equities analysts have recently commented on ENTL shares. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub cut Entellus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 8th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Entellus Medical in a research note on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $21.86.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in shares of Entellus Medical by 53.8% during the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after purchasing an additional 2,594 shares during the period. Nationwide Fund Advisors increased its position in shares of Entellus Medical by 61.7% during the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 2,635 shares during the period. First Mercantile Trust Co. increased its position in shares of Entellus Medical by 45.3% during the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after purchasing an additional 2,557 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of Entellus Medical by 5.6% during the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Entellus Medical by 61.7% during the second quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after purchasing an additional 4,533 shares during the period. Institutional investors and hedge funds own 70.27% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.